John Schmid

Mr. John P.
Schmid is an Independent Director at Blossomhill Therapeutics, Inc., an Independent Director at Design Therapeutics, Inc., an Independent Director at AnaptysBio, Inc., a Chairman at Speak, Inc., an Independent Director at First Tracks Biotherapeutics, Inc. and an Independent Director at Helix Acquisition Corp.
III.
He is on the Board of Directors at Blossomhill Therapeutics, Inc., Bright Peak Therapeutics, Inc., Design Therapeutics, Inc., AnaptysBio, Inc., First Tracks Biotherapeutics, Inc. and Helix Acquisition Corp.
III.
Mr. Schmid was previously employed as an Independent Director by Helix Acquisition Corp.
II, a Lead Independent Director by Xeris Biopharma Holdings, Inc., an Independent Director by Helix Acquisition Corp., an Independent Director by Poseida Therapeutics, Inc., an Independent Non-Executive Director by Xeris Pharmaceuticals, Inc., an Independent Director by Neos Therapeutics, Inc., a Chief Financial Officer by Auspex Pharmaceuticals, Inc., a Chief Financial Officer & Secretary by Trius Therapeutics, Inc., a Chief Financial Officer by GeneFormatics, Inc., a Chief Financial Officer by Endonetics, Inc., a President & Director by San Diego Venture Group, an Associate by Idanta Partners Ltd., a Vice President by Home Federal Savings & Loan Association (Nampa, Idaho), a Chief Financial Officer by Allylix, Inc., a Chief Financial Officer by Cengent Therapeutics, Inc., a Vice President by Indiana Bank & Trust Co., and a Chief Financial Officer by Vessix Vascular, Inc. He also served on the board at Forge Therapeutics, Inc. and Patara Pharma LLC.
He received his undergraduate degree from Wesleyan University and an MBA from the University of San Diego.